Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma

Journal of Histochemistry and Cytochemistry

Volumn 62, Issue 8, 2014, Pages 547-555

  Gyöngyösi, Benedek ^a   Végh, Éva ^c   Járay, Balázs ^a   Székely, Eszter ^a   Fassan, Matteo ^d   Bodoky, György ^c   Schaff, Zsuzsa ^a,b   Kiss, András ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c Department of Oncology United Saint Stephen and Saint Laslo Hospital and Outpatient Clinics   (Hungary)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

FNAB; hepatocellular carcinoma; microRNA; sorafenib; survival

Indexed keywords

MICRORNA; MICRORNA 122; MICRORNA 140; MICRORNA 17 5P; MICRORNA 18A; MICRORNA 195; MICRORNA 21; MICRORNA 210; MICRORNA 214; MICRORNA 221; MICRORNA 222; MICRORNA 223; MICRORNA 224; MICRORNA 328; MICRORNA 34A; RNA; SMALL UNTRANSLATED RNA; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CORRELATIONAL STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TREATMENT OUTCOME; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SURVIVAL ANALYSIS;

EID: 84904987193     PISSN: 00221554     EISSN: 15515044     Source Type: Journal    
DOI: 10.1369/0022155414537277     Document Type: Article

References (48)

1. Ali S,Saleh H,Sethi S,Sarkar FH,Philip PA.MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer.Br J Cancer. 2012;107:1354-1360.
2. Andersen CL,Jensen JL,Orntoft TF.Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets.Cancer Res. 2004;64:5245-5250.
3. Baek KK,Kim JH,Uhm JE,Park SH,Lee J,Park JO,Park YS,Kang WK,Lim HY.Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.Oncology. 2011;80:167-174.
4. Bai S,Nasser MW,Wang B,Hsu SH,Datta J,Kutay H,Yadav A,Nuovo G,Kumar P,Ghoshal K.MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.J Biol Chem. 2009;284:32015-32027.
5. Calin GA,Ferracin M,Cimmino A,Di Leva G,Shimizu M,Wojcik SE,Iorio MV,Visone R,Sever NI,Fabbri M,Iuliano R,Palumbo T,Pichiorri F,Roldo C,Garzon R,Sevignani C,Rassenti L,Alder H,Volinia S,Liu CG,Kipps TJ,Negrini M,Croce CM.A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.N Engl J Med. 2005;353:1793-1801.
6. Chen L,Jiang M,Yuan W,Tang H.miR-17-5p as a novel prognostic marker for hepatocellular carcinoma.J Invest Surg. 2012;25:156-161.
7. Chen L,Shi Y,Jiang CY,Wei LX,Lv YL,Wang YL,Dai GH.Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.Int J Biol Markers. 2011;26:108-116.
8. Cheng AL,Kang YK,Chen Z,Tsao CJ,Qin S,Kim JS,Luo R,Feng J,Ye S,Yang TS,Xu J,Sun Y,Liang H,Liu J,Wang J,Tak WY,Pan H,Burock K,Zou J,Voliotis D,Guan Z.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol. 2009;10:25-34.
9. Chu JS,Ge FJ,Zhang B,Wang Y,Silvestris N,Liu LJ,Zhao CH,Lin L,Brunetti AE,Fu YL,Wang J,Paradiso A,Xu JM.Expression and prognostic value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma.J Exp Clin Cancer Res. 2013;32:16.
10. Doleshal M,Magotra AA,Choudhury B,Cannon BD,Labourier E,Szafranska AE.Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues.J Mol Diagn. 2008;10:203-211.
11. Dweep H,Sticht C,Pandey P,Gretz N.miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes.J Biomed Inform. 2011;44:839-847.
12. Fassina A,Cappellesso R,Simonato F,Lanza C,Marzari A,Fassan M.Fine needle aspiration of non-small cell lung cancer: current state and future perspective.Cytopathology. 2012;23:213-219.
13. Fassina A,Fabbro M,Cappellesso R,Fassan M.Seeding of tumour cells after fine needle aspiration cytology in liver nodules: myth or reality?.Cytopathology. 2010;21:413-414.
14. Giordano S,Columbano A.MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?.Hepatology. 2013;57:840-847.
15. Gramantieri L,Fornari F,Callegari E,Sabbioni S,Lanza G,Croce CM,Bolondi L,Negrini M.MicroRNA involvement in hepatocellular carcinoma.J Cell Mol Med. 2008;12:2189-2204.
16. Hagiwara S,Kudo M,Nagai T,Inoue T,Ueshima K,Nishida N,Watanbe T,Sakurai T.Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.Br J Cancer. 2012;106:1997-2003.
17. Jemal A,Bray F,Center MM,Ferlay J,Ward E,Forman D.Global cancer statistics.CA Cancer J Clin. 2011;61:69-90.
18. Karakatsanis A,Papaconstantinou I,Gazouli M,Lyberopoulou A,Polymeneas G,Voros D.Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance.Mol Carcinog. 2013;52:297-303.
19. Kitano M,Rahbari R,Patterson EE,Steinberg SM,Prasad NB,Wang Y,Zeiger MA,Kebebew E.Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples.Thyroid. 2012;22:285-291.
20. Lachenmayer A,Alsinet C,Chang CY,Llovet JM.Molecular approaches to treatment of hepatocellular carcinoma.Dig Liver Dis 42 Suppl. 2010;3:S264-272.
21. Li H,Li Y,Liu D,Sun H,Liu J.miR-224 is Critical for Celastrol-Induced Inhibition of Migration and Invasion of Hepatocellular Carcinoma Cells.Cell Physiol Biochem. 2013;32:448-458.
22. Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,Raoul JL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,Borbath I,Haussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med. 2008;359:378-390.
23. Lu J,Getz G,Miska EA,Alvarez-Saavedra E,Lamb J,Peck D,Sweet-Cordero A,Ebert BL,Mak RH,Ferrando AA,Downing JR,Jacks T,Horvitz HR,Golub TR.MicroRNA expression profiles classify human cancers.Nature. 2005;435:834-838.
24. Lu S,Wang S,Geng S,Ma S,Liang Z,Jiao B.Upregulation of microRNA-224 confers a poor prognosis in glioma patients.Clin Transl Oncol. 2013;15:569-574.
25. Lujambio A,Lowe SW.The microcosmos of cancer.Nature. 2012;482:347-355.
26. Mencia N,Selga E,Noe V,Ciudad CJ.Underexpression of miR-224 in methotrexate resistant human colon cancer cells.Biochem Pharmacol. 2011;82:1572-1582.
27. Minguez B,Lachenmayer A.Diagnostic and prognostic molecular markers in hepatocellular carcinoma.Dis Markers. 2011;31:181-190.
28. Murakami Y,Yasuda T,Saigo K,Urashima T,Toyoda H,Okanoue T,Shimotohno K.Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.Oncogene. 2006;25:2537-2545.
29. Patel SH,Kneuertz PJ,Delgado M,Kooby DA,Staley CA,El-Rayes BF,Kauh JS,Sarmiento JM,Hanish S,Cohen C,Farris AB,Maithel SK.Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.Ann Surg Oncol. 2011;18:3384-3390.
30. Personeni N,Rimassa L,Pressiani T,Destro A,Ligorio C,Tronconi MC,Bozzarelli S,Carnaghi C,Di Tommaso L,Giordano L,Roncalli M,Santoro A.Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.J Cancer Res Clin Oncol. 2013;139:1179-1187.
31. Petriella D,Galetta D,Rubini V,Savino E,Paradiso A,Simone G,Tommasi S.Molecular profiling of thin-prep FNA samples in assisting clinical management of non-small-cell lung cancer.Mol Biotechnol. 2013;54:913-919.
32. Pinter M,Sieghart W,Hucke F,Graziadei I,Vogel W,Maieron A,Konigsberg R,Weissmann A,Kornek G,Matejka J,Stauber R,Buder R,Grunberger B,Schoniger-Hekele M,Muller C,Peck-Radosavljevic M.Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.Aliment Pharmacol Ther. 2011;34:949-959.
33. Scartozzi M,Faloppi L,Svegliati Baroni G,Loretelli C,Piscaglia F,Iavarone M,Toniutto P,Fava G,De Minicis S,Mandolesi A,Bianconi M,Giampieri R,Granito A,Facchetti F,Bitetto D,Marinelli S,Venerandi L,Vavassori S,Gemini S,D'Errico A,Colombo M,Bolondi L,Bearzi I,Benedetti A,Cascinu S.VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study.Int J Cancer. 2014;:.
34. Shen SN,Wang LF,Jia YF,Hao YQ,Zhang L,Wang H.Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer.Diagn Pathol. 2013;8:69.
35. Simonato F,Ventura L,Sartori N,Cappellesso R,Fassan M,Busund LT,Fassina A.Detection of microRNAs in archival cytology urine smears.PLoS One. 2013;8:e57490.
36. Takeda H,Nishikawa H,Iguchi E,Ohara Y,Sakamoto A,Hatamaru K,Henmi S,Saito S,Nasu A,Komekado H,Kita R,Kimura T,Osaki Y.Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib.Mol Clin Oncol. 2013;1:241-248.
37. Tomimaru Y,Eguchi H,Nagano H,Wada H,Tomokuni A,Kobayashi S,Marubashi S,Takeda Y,Tanemura M,Umeshita K,Doki Y,Mori M.MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells.Br J Cancer. 2010;103:1617-1626.
38. Tsuchiya K,Asahina Y,Matsuda S,Muraoka M,Nakata T,Suzuki Y,Tamaki N,Yasui Y,Suzuki S,Hosokawa T,Nishimura T,Ueda K,Kuzuya T,Nakanishi H,Itakura J,Takahashi Y,Kurosaki M,Enomoto N,Izumi N.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.Cancer. 2014;120:229-237.
39. Varnholt H,Drebber U,Schulze F,Wedemeyer I,Schirmacher P,Dienes HP,Odenthal M.MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma.Hepatology. 2008;47:1223-1232.
40. Wang X,Chen J,Li F,Lin Y,Zhang X,Lv Z,Jiang J.MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of beta-catenin.Biochem Biophys Res Commun. 2012;428:525-531.
41. Wang Y,Lee AT,Ma JZ,Wang J,Ren J,Yang Y,Tantoso E,Li KB,Ooi LL,Tan P,Lee CG.Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target.J Biol Chem. 2008;283:13205-13215.
42. Wang Y,Ren J,Gao Y,Ma JZ,Toh HC,Chow P,Chung AY,Ooi LL,Lee CG.MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival.PLoS One. 2013;8:e68744.
43. Wilhelm SM,Carter C,Tang L,Wilkie D,McNabola A,Rong H,Chen C,Zhang X,Vincent P,McHugh M,Cao Y,Shujath J,Gawlak S,Eveleigh D,Rowley B,Liu L,Adnane L,Lynch M,Auclair D,Taylor I,Gedrich R,Voznesensky A,Riedl B,Post LE,Bollag G,Trail PA.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.Cancer Res. 2004;64:7099-7109.
44. Xia H,Ooi LL,Hui KM.MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.Hepatology. 2013;58:629-641.
45. Xu Y,Xia F,Ma L,Shan J,Shen J,Yang Z,Liu J,Cui Y,Bian X,Bie P,Qian C.MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest.Cancer Lett. 2011;310:160-169.
46. Yang F,Li QJ,Gong ZB,Zhou L,You N,Wang S,Li XL,Li JJ,An JZ,Wang DS,He Y,Dou KF.MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment.Technol Cancer Res Treat. 2013;13:77-86.
47. Zhang Y,Takahashi S,Tasaka A,Yoshima T,Ochi H,Chayama K.Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma.J Gastroenterol Hepatol. 2013;28:565-575.
48. Zhou C,Liu J,Li Y,Liu L,Zhang X,Ma CY,Hua SC,Yang M,Yuan Q.microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.FEBS Lett. 2011;585:1828-1834.